SLC5A2 and acute myeloid leukemia: Our results unexpectedly associate SGLT2 inhibitor use with a higher risk of mortality, an effect that was persistent in multiple myeloma and acute myeloid leukemia after controlling for both chronic kidney disease and congestive heart failure.